Angel investors shy away from biotech

"Angel investors often avoid biotech startups because of long and costly development times of biotech products, as well as a tendency for venture capitalists (VCs) to set over-diluting terms when entering in follow-on financing rounds. These trends are exacerbating an early-stage funding gap in the biotech sector..."

From Bioentrepreneur: